An Update on Somatic Treatments for Suicide Risk

Area of Science:

• Psychiatry
• Public Health
• Pharmacology

Background:

• Suicide is a significant global health concern, necessitating effective prevention strategies.
• Pharmacologic and neuromodulatory interventions are key components of suicide prevention efforts.
• Understanding the direct effects of these treatments on suicide diathesis, beyond symptom improvement, is crucial.

Purpose of the Study:

• To review evidence on pharmacologic and neuromodulatory interventions for suicide prevention.
• To differentiate between direct effects on suicide diathesis and symptom-mediated effects.
• To synthesize findings across major psychiatric disorders.

Main Methods:

• Scoping review of randomized controlled trials (RCTs), meta-analyses, and observational studies.
• Appraisal of studies based on design, sample size, population, and outcome definitions.
• Examination of associations between treatments and suicidal ideation, attempts, or deaths.

Main Results:

• Lithium and clozapine showed reductions in suicidal behavior in specific disorders.
• Intravenous ketamine rapidly reduced suicidal ideation, with potential effects beyond antidepressant action.
• Antidepressants primarily reduced suicidal ideation via symptom improvement; evidence for direct effects on suicidal behavior was limited.
• Opioid use disorder medications were linked to lower suicide and overdose mortality.
• Electroconvulsive therapy and transcranial magnetic stimulation showed rapid reduction in suicidal ideation.

Conclusions:

• Somatic treatments can reduce suicidal ideation and behavior, often through mood-stabilizing or antidepressant mechanisms.
• Lithium, clozapine, and intravenous ketamine may offer direct benefits for suicide diathesis.
• Targeting the underlying diathesis for suicidal behavior represents an under-explored therapeutic avenue.
• Large, adequately powered RCTs are essential to confirm the efficacy of somatic treatments for suicidal behavior.